LYNBROOK, N.Y., Sept. 2, 2016 /PRNewswire/ -- BioSpecifics
Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that
originated and continues to develop collagenase based-therapies
with a first in class collagenase-based product collagenase
clostridium histolyticum, or CCH, marketed as XIAFLEX®
in the U.S. and Xiapex® in Europe, today announced that BioSpecifics'
President, Tom Wegman, will present
a corporate overview at the following upcoming conferences.
- NewsMakers in the Biotech Industry Conference at 9:00 a.m. ET on Friday,
September 9, 2016 in New York,
NY. Link: http://wsw.com/webcast/biocentury3/bstc.
- Rodman & Renshaw 18th Annual Global Investment Conference
at 4:40 p.m. ET on Monday, September 12, 2016 in New York, NY. Link:
http://wsw.com/webcast/rrshq26/bstc
A live audio webcast of each presentation can be accessed under
"Events and Presentation" in the Investors section of the Company's
website at www.biospecifics.com. An archived replay of the webcast
will be available for 30 days after the live event concludes.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company
that has developed injectable collagenase for twelve clinical
indications to date. Injectable collagenase is marketed as XIAFLEX®
in the U.S. for the treatment of Dupuytren's contracture and
Peyronie's disease by BioSpecifics' partner, Endo International plc
(Endo). XIAFLEX® is also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and also for Peyronie's disease
in Europe and Australia. Endo has the following
partnerships outside the U.S. for these two indications; Swedish
Orphan Biovitrum AB has marketing rights for Xiapex® (the
European tradename for XIAFLEX) in 71 Eurasian and African
countries, Actelion Pharmaceuticals Ltd. has marketing rights
in Canada and Australia and Asahi Kasei Pharma
Corporation has marketing rights in Japan. Sobi is selling
Xiapex in Europe for the treatment of Dupuytren's
contracture and Peyronie's disease. Asahi is selling XIAFLEX for
the treatment of Dupuytren's contracture in Japan. Actelion is
selling XIAFLEX in Canada and Australia for the
treatment of Dupuytren's contracture and in Australia for
Peyronie's disease. The XIAFLEX development pipeline includes
several additional promising indications. Endo is currently
managing development of CCH for cellulite, adhesive capsulitis,
human and canine lipoma, lateral hip fat and plantar fibromatosis.
BioSpecifics is managing the development of CCH for uterine
fibroids and plans to initiate clinical development in the second
half of 2016. For more information, please
visit www.biospecifics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-two-upcoming-september-conferences-300318721.html
SOURCE BioSpecifics Technologies Corp.